The current published literature demonstrates that Pelareorep-based reovirus therapy, alone or combined with GM-CSF, is generally safe and well tolerated across diverse glioma patient populations, including recurrent malignant gliomas, newly diagnosed GBM, and pediatric high-grade gliomas (Table 7) [135,136,137,138]. The gene discussed is CSF2; the disease is glioblastoma.